# US 2021/0403432 A1 · Compositions and methods for suppressing and/or treating metabolic diseases and/or a clinical condition thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0403432 A1
- Document ID: US20210403432A1
- Status: Published application
- Kind: A1
- Application number: 17/285,413
- Filed: 2019-10-14
- Published: 2021-12-30
- Earliest claimed: 2018-10-15
- Assignees: Ck Biotech
- Applicants: CK Biotech Inc.
- Inventors: Kang-Yell Choi; Seol Hwa Seo; Eunhwan Kim
- Web page: https://patentgrep.com/patent/US20210403432A1

## CPC

- A23L 33/10: using additives (addition of substantially indigestible substances A23L33/21)
- C07D 215/38: Nitrogen atoms (nitro radicals C07D215/18)
- A61P 3/00: Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00)
- A61P 3/04: Anorexiants; Antiobesity agents
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- C07C 39/215: containing [IMAGE cpc-sch-C07C-0957.gif], e.g. diethylstilbestrol
- C07C 229/36: with at least one amino group and one carboxyl group bound to the same carbon atom of the carbon skeleton
- C07C 237/48: having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a six-membered aromatic ring being part of a condensed ring system of the same carbon skeleton
- C07D 207/44: having three double bonds between ring members or between ring members and non-ring members
- C07D 209/36: in position 3, e.g. adrenochrome
- C07D 209/40: Nitrogen atoms, not forming part of a nitro radical, e.g. isatin semicarbazone
- C07D 217/16: substituted by oxygen atoms
- C07D 217/20: with oxygen atoms directly attached to the aromatic ring of said aralkyl radical, e.g. papaverine
- C07D 239/42: One nitrogen atom (nitro radicals C07D239/30)
- C07D 295/08: substituted by singly bound oxygen or sulfur atoms
- C07D 295/088: to an acyclic saturated chain
- C07D 309/36: with oxygen atoms directly attached to ring carbon atoms
- C07D 309/38: one oxygen atom in position 2 or 4, e.g. pyrones
- C07D 311/30: not hydrogenated in the hetero ring, e.g. flavones
- C07D 471/04: Ortho-condensed systems
- C07D 487/04: Ortho-condensed systems
- C07D 487/22: in which the condensed system contains four or more hetero rings
- C07D 491/048: the oxygen-containing ring being five-membered
- C07D 498/04: Ortho-condensed systems
- C07D 513/04: Ortho-condensed systems
- C07D 513/14: Ortho-condensed systems
- G01N 33/6893: {related to diseases not provided for elsewhere}
- A61K 9/0014: {Skin, i.e. galenical aspects of topical compositions (non-active ingredients are additionally classified in A61K47/00; A61K9/0009, A61K9/0021, A61K9/7015, A61K9/7023 take precedence; cosmetic preparations A61K8/00, A61Q; preparations for wound dressings or bandages A61L26/00)}
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 9/107: Emulsions {; Emulsion preconcentrates; Micelles (composition of emulsions A61K47/00)}
- G01N 2333/4703: Regulators; Modulating activity
- G01N 2800/042: Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism
- G01N 2800/044: Hyperlipemia or hypolipemia, e.g. dyslipidaemia, obesity
- G01N 2800/085: Liver diseases, e.g. portal hypertension, fibrosis, cirrhosis, bilirubin
- A23L: FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF (preservation thereof A23B)
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Therapeutic compositions comprising one or more agents that inhibit CXXC5-DVL interface, and methods of administering those therapeutic compositions to model, treat, reduce resistance to treatment, prevent, and diagnose a condition/disease associated with a metabolic disease or a related clinical condition thereof, are disclosed.

## Claims

### Claim 1

A compound of Formula I,
wherein:
X is O or N optionally substituted with R1;
R1 is hydrogen, hydroxy, alkyl, alkenyl, or an alkoxy optionally substituted with alkyl, alkenyl, haloalkyl, aryl, or benzyl; or R1 is hydrogen, alkyl, alkenyl, or an alkoxy substituted with butyl, alkenyl, haloalkyl, aryl, or benzyl,
R2 is hydrogen, nitro, halogen, alkyl, alkenyl, haloalkyl, alkoxy, haloalkoxy, or a carboxy,
R3 is hydrogen, nitro, halogen, alkyl, alkenyl, haloalkyl, alkoxy, haloalkoxy, or a carboxy; or R3 is hydrogen, fluorine, iodine, astatine, alkyl, alkenyl, haloalkyl, OCF3, ethoxy, propyloxy, butyloxy, haloalkoxy, or a carboxy, and/or wherein when R3 is bromine or chlorine, R4 is not hydrogen; and/or wherein when R3 is chlorine, R4 is not chlorine,
R4 is hydrogen, nitro, halogen, alkyl, alkenyl, haloalkyl, alkoxy, haloalkoxy, or a carboxy; or R4 is hydrogen, nitro, fluorine, bromine, iodine, astatine, alkyl, alkenyl, haloalkyl, alkoxy, haloalkoxy, or a carboxy; and/or wherein when R4 is chlorine, R3 is not hydrogen or nitro,
R5 is hydrogen, nitro, halogen, alkyl, alkenyl, haloalkyl, alkoxy, haloalkoxy, or a carboxy.

### Claim 2 (depends on 1)

The compound according to claim 1, wherein X is N and R1 is hydroxy or alkoxy optionally substituted with alkyl, alkenyl, haloalkyl, aryl, or benzyl.

### Claim 3 (depends on 1, 2)

The compound according to claim 1 or claim 2, wherein R1 is alkoxy optionally substituted with alkyl, butyl, alkenyl, haloalkyl, aryl, or benzyl.

### Claim 4 (depends on 1, 2, 3)

The compound according to any one of claims 1-3, wherein the compound is

### Claim 5

A compound of Formula II,
wherein:
R6, R7, R8, R9, and R10 are independently hydrogen, halogen, hydroxy, alkyl, haloalkyl, alkoxy, or
R11 is C1-C6 alkyl, C1-C6 alkenyl, N, diimide, each substituted with R12,
R12 is
R13 is hydrogen or alkyl optionally substituted with hydrogen, halogen, hydroxy, alkoxy, or haloalkyl;
each R14, each R15, and each R16 are independently hydrogen; halogen; haloalkyl optionally substituted with hydrogen, halogen, hydroxy, or alkoxy; alkyl optionally substituted with hydrogen, halogen, hydroxy, alkoxy, or haloalkyl; alkoxy optionally substituted with hydrogen, halogen, hydroxy, alkoxy, or haloalkyl; alkenyl optionally substituted with hydrogen, halogen, hydroxy, alkoxy, or haloalkyl; or alkynyl optionally substituted with hydrogen, halogen, hydroxy, alkoxy, or haloalkyl;
X1, X2 and X3 are independently carbon, nitrogen, oxygen, or sulfur.

### Claim 6 (depends on 5)

The compound according to claim 5, wherein the compound is

### Claim 7

A compound of Formula III,
wherein:
each R17 is independently hydrogen; halogen; haloalkyl optionally substituted with hydrogen, halogen, hydroxy, or alkoxy; alkyl optionally substituted with hydrogen, halogen, hydroxy, alkoxy, or haloalkyl; alkoxy optionally substituted with hydrogen, halogen, hydroxy, alkoxy, or haloalkyl; alkenyl optionally substituted with hydrogen, halogen, hydroxy, alkoxy, or haloalkyl; or alkynyl optionally substituted with hydrogen, halogen, hydroxy, alkoxy, or haloalkyl;
X4 and X5 are independently nitrogen, oxygen, or sulfur.

### Claim 8 (depends on 7)

The compound according to claim 7, wherein each R17 is independently halogen or hydroxy.

### Claim 9 (depends on 7, 8)

The compound according to claim 7 or claim 8, wherein the compound is

### Claim 10

A compound of Formula IV,
wherein:
each R18 and R19 are independently hydrogen; halogen; hydroxy; haloalkyl optionally substituted with hydrogen, halogen, hydroxy, or alkoxy; alkyl optionally substituted with hydrogen, halogen, hydroxy, alkoxy, or haloalkyl; alkoxy optionally substituted with hydrogen, halogen, hydroxy, alkoxy, or haloalkyl; alkenyl optionally substituted with hydrogen, halogen, hydroxy, alkoxy, or haloalkyl; or alkynyl optionally substituted with hydrogen, halogen, hydroxy, alkoxy, or haloalkyl.

### Claim 11 (depends on 10)

The compound according to claim 10, wherein the compound is

### Claim 12

A compound of Formula V,
wherein:
each R and each R are independently hydrogen; halogen; haloalkyl optionally substituted with hydrogen, halogen, hydroxy, or alkoxy; alkyl optionally substituted with hydrogen, halogen, hydroxy, alkoxy, or haloalkyl; alkoxy optionally substituted with hydrogen, halogen, hydroxy, alkoxy, or haloalkyl; alkenyl optionally substituted with hydrogen, halogen, hydroxy, alkoxy, or haloalkyl; or alkynyl optionally substituted with hydrogen, halogen, hydroxy, alkoxy, or haloalkyl.

### Claim 13 (depends on 12)

The compound according to claim 12, wherein the compound is

### Claim 14

A compound of Formula VI,
wherein:
each R20 and each R21 are independently hydrogen; halogen; haloalkyl optionally substituted with hydrogen, halogen, hydroxy, or alkoxy; alkyl optionally substituted with hydrogen, halogen, hydroxy, alkoxy, haloalkyl, or a carbonyl, wherein the carbonyl is optionally substituted with hydrogen, halogen, alkyl, hydroxy, alkoxy, or haloalkyl;
alkoxy optionally substituted with hydrogen, halogen, hydroxy, alkoxy, or haloalkyl;
alkenyl optionally substituted with hydrogen, halogen, hydroxy, alkoxy, or haloalkyl; or
alkynyl optionally substituted with hydrogen, halogen, hydroxy, alkoxy, or haloalkyl.

### Claim 15 (depends on 14)

The compound according to claim 14, wherein the compound is

### Claim 16 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15)

The compound according to any one of the claims 1-15, wherein the compound inhibits CXXC5-DVL interface.

### Claim 17 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16)

A pharmaceutical composition comprising at least one compound according to any one of claims 1-16 and/or a pharmaceutically acceptable hydrate, salt, metabolite, or carrier thereof.

### Claim 18 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17)

A method of treating a metabolic disease or a similar condition, comprising:
administering to a subject at least one therapeutically effective dose of at least one agent that reduces and/or inhibits the CXXC5-DVL interaction; or
administering to a subject at least one therapeutically effective dose of at least one agent comprising at least one compound according to claims 1-16 and/or at least one composition according to claim 17.

### Claim 19 (depends on 18)

The method according to claim 18, further comprising:
detecting upregulated expression of CXXC5 in the subject.

### Claim 20 (depends on 18, 19)

The method according to claim 18 or claim 19, further comprising the step of:
identifying the subject as at risk for a metabolic disease or a similar condition.

### Claim 21 (depends on 18, 19, 20)

The method according to any one of claims 18-20, wherein the subject exhibits abnormal lipid profile and/or blood glucose levels.

### Claim 22 (depends on 18, 19, 20, 21)

The method according to any one of the claims 18-21, wherein the subject is diagnosed with obesity, diabetes, non-alcoholic fatty liver disease (NAFLD), and/or non-alcoholic steatohepatitis (NASH).

### Claim 23 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22)

The method according to any one of claims 18-22, wherein the at least one agent that reduces and/or inhibits the CXXC5-DVL interaction comprises at least one compound according to claims 1-16 and/or at least one composition according to claim 17.

### Claim 24 (depends on 18, 19, 20, 21, 22, 23)

The method according to any one of claims 18-23, wherein the subject is a human or an animal.

### Claim 25 (depends on 18, 19, 20, 21, 22, 23, 24)

The method according to any one of claims 18-24, wherein the at least one agent is administered orally or intravenously.

### Claim 26

A method of detecting one or more metabolic disease markers, comprising:
providing a sample of blood, cells, or tissue from a subject; and
detecting one or more markers in the sample, wherein the one or more markers comprise CXXC5 and/or β-catenin.

### Claim 27 (depends on 26)

The method according to claim 26, wherein the metabolic disease comprises obesity, diabetes, non-alcoholic fatty liver disease (NAFLD), and/or non-alcoholic steatohepatitis (NASH).

### Claim 28 (depends on 26, 27)

The method according to claims 26-27, wherein CXXC5 is overexpressed in the liver, adipose tissue, and/or pancreas of the subject.

### Claim 29 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16)

A method of suppressing the activity of CXXC5, comprising:
providing a subject at least one therapeutically effective dose of at least one compound according to any one of claims 1-16, or a pharmaceutically acceptable salt or metabolite thereof.

### Claim 30 (depends on 29)

The method according to claim 29, wherein the subject is a human, an animal, a cell, and/or a tissue.
